Lee Ainslie Novo Cure LTD Transaction History

Maverick Capital LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $44,447 - $72,218	-592 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $68,772 - $115,173	592 New	592 $69,000
Q4 2020 Feb 16, 2021	SELL	$112.16 - $174.14 $804,748 - $1.25 Million	-7,175 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$58.05 - $111.31 $745,710 - $1.43 Million	-12,846 Reduced 64.16%	7,175 $799,000
Q2 2020 Aug 14, 2020	BUY	$57.2 - $74.41 $1.15 Million - $1.49 Million	20,021 New	20,021 $1.19 Million

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.